Schrödinger (SDGR) Q3 2026 Earnings Call Transcript

Schrödinger reported Q3 2026 revenue of $64.5 million, up 19% year over year, while ACV rose 17% to $44.7 million (24% excluding contribution ACV). Management raised full-year ACV guidance to $222 million–$232 million from $218 million–$228 million and drug discovery revenue guidance to $75 million–$85 million from $65 million–$75 million, citing performance and a Structure Therapeutics milestone. Operating expenses fell 13% to $64 million, but net loss widened to $37.7 million from $32.8 million; hosted licensing transition reduced software gross margin to 75% from 77% and temporarily weighs on reported revenue. Bunsen handled about 80% of internal high-throughput calculations, and the company said it had $373 million in cash and marketable securities at Sept. 30, 2026.

Analysis

The important signal is the divergence between underlying demand and reported software revenue: ACV growth (24% excluding contribution ACV) is stronger than recognized software growth, but hosted migration also lowers gross margin and delays revenue recognition. That can create a favorable setup if investors overreact to reported revenue; it is not yet proof of improving unit economics. Verify renewal timing, hosted retention/expansion, cloud delivery costs, and the precise basis of management’s $2–3 million revenue sensitivity before modeling a quarterly run rate.

For Schrödinger (SDGR), the near-term catalyst is conversion of Bunsen and predictive-toxicology evaluations into paid usage and ACV. Internal compute-cluster adoption is evidence of workflow utility, not evidence of customer monetization: management declined to quantify token consumption or willingness to pay, and Bunsen remains in early access. Material science is a longer-dated option, with services-heavy adoption potentially limiting near-term software margins even as workflow automation could eventually improve scalability.

Drug-discovery revenue is milestone-lumpy, so the raised outlook should not be capitalized like recurring software growth. Structure Therapeutics’ program advancement supports the possibility of future collaboration value, but the call provides no basis to infer a material financial impact for GPCR. Similarly, the accepted NDA and other pipeline events offer contingent upside, not dependable quarterly revenue.

Contrarian read: investors may focus on AI optionality and guidance raises while underweighting hosted-mix margin drag and the gap between product enthusiasm and disclosed customer monetization. Without valuation and price-action data, avoid chasing the print; falsification of the constructive SDGR view would be ACV growth decelerating, hosted adoption failing to translate into paid expansion, or software gross margin continuing to compress without improving retention or usage.

Key Decisions for Investors

• SDGR: Favor a staged long entry on post-results weakness rather than chasing the announcement; the thesis is durable ACV expansion, not the milestone-boosted revenue headline. Reassess if next-quarter ACV growth materially slows or software gross margin declines further without evidence of hosted customer expansion.
• SDGR: Track Bunsen open-beta conversion, paid token/throughput usage, predictive-toxicology evaluation-to-contract conversion, and hosted renewal/expansion rates over the next 1–3 months. Treat internal utilization and positive customer feedback as leading indicators, not booked demand.
• GPCR: Watch for clinical updates on the oral amylin program, but do not infer a material GPCR earnings catalyst from SDGR’s milestone receipt; the amount and GPCR’s economics are not disclosed here.
• Before adding to SDGR, verify the stock’s valuation versus recurring ACV growth and clarify management’s hosted-revenue sensitivity and cloud cost trajectory. If ACV remains strong while reported revenue lags, that supports the timing-distortion thesis; if ACV weakens too, the thesis is impaired.